The election in November may determine whether certain drug cost policies are expanded or continue to exist, Reed Abelson and Rebecca Robbins of The New York Times reports. Democratic nominee Vice President Kamala Harris has vowed to extend President Biden’s policies to more drugs and more Americans, with plans to use savings from expanding negotiations to help pay for a new proposal to cover long-term care at home for people on Medicare. Republican nominee former President Donald Trump has offered few specifics on what he would do on drug pricing. Last week, Trump reversed his position on a policy he proposed in his first term, which was to tie drug prices to what other wealthy countries pay. Companies in the space include Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), Eli Lilly (LLY), Merck (MRK), Pfizer (PFE), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Roche (RHHBY), Novartis (NVS).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- AstraZeneca, CSPC deal shows Lp(a) space remains hot, says BMO Capital
- Bristol Myers price target raised to $43 from $42 at Barclays
- Trump backs off support of controversial drug pricing plan, STAT reports
- Bristol Myers announces FDA approval of Opdivo for treatment of NSCLC
- Stellantis cuts 2024 targets, TPG acquires AT&T’s DirecTV stake: Morning Buzz
Questions or Comments about the article? Write to editor@tipranks.com